Here is what trans-resveratrol is, where SIRT1 research stops short in people, which doses human trials used and what is known when it is paired with NMN.
Trans-resveratrol is the resveratrol form behind most research. It activates SIRT1 in the lab, and SIRT1 is a sirtuin protein linked to aging. In the body, however, oral resveratrol is rapidly broken down, so direct SIRT1 activation in people hasn't been proven. Human trials, typically at 150 to 1,000 mg a day, show small, inconsistent effects. No human study shows that it slows aging.
The molecule resveratrol comes as two stereoisomers, trans-resveratrol and cis-resveratrol, which are two shapes of one compound. Trans is the more stable shape and the one that most lab and human research has used.
Pick a product that tells you how much trans-resveratrol it holds. If the label says only "resveratrol", or names a plant extract with no trans-resveratrol amount, the dose is hard to judge. A batch Certificate of Analysis can confirm it.
Sirtuins (SIRT1-7) are a protein family. They help regulate cells, repair DNA, control metabolism and resist stress, and each needs NAD+ as a co-substrate to function. Resveratrol increases SIRT1 activity in lab studies, but researchers have debated how directly. Whether that holds at the doses people take is unproven.
People pair resveratrol with an NAD+ precursor such as NMN, which raises blood NAD+ in small human trials, because sirtuins need NAD+. The logic seems sound on paper. Still, no human trial has shown the combination beats either on its own, or that either one slows aging. Looking at human outcomes so far, a 2024 meta-analysis of resveratrol trials in metabolic syndrome found lower blood pressure, higher triglycerides and no change in HDL cholesterol or waist size, and it described the results as borderline.